Lead Product(s) : Perfluorobutane
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Perflubutane is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 14, 2017
Lead Product(s) : Perfluorobutane
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorobutane
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sonazoid (Perflubutane) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Liver Diseases.
Product Name : Sonazoid
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 07, 2017
Lead Product(s) : Perfluorobutane
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorobutane
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : National Heart, Lung, and Blood Institute | GE Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Noninvasive Real-time Intracardiac Pressure Measurements Using Subharmonic Ultrasound
Details : Sonazoid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Heart Failure.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 10, 2017
Lead Product(s) : Perfluorobutane
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : National Heart, Lung, and Blood Institute | GE Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorobutane
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : GE Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection
Details : Sonazoid is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Graft Rejection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 11, 2016
Lead Product(s) : Perfluorobutane
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : GE Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Perfluorobutane
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : National Cancer Institute | GE Healthcare | Siemens Medical Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Contrast Ultrasound Detection of Sentinel Lymph Nodes
Details : Sonazoid (Perflubutane) is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Sonazoid
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 12, 2016
Lead Product(s) : Perfluorobutane
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : National Cancer Institute | GE Healthcare | Siemens Medical Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
